Zydus Life enters exclusive licensing and commercialisation agreement for oncology product

Zydus Lifesciences Ltd. on Wednesday, November 26, said it has entered an exclusive licensing and commercialisation agreement with US-based RK Pharma Inc for a novel sterile injectable 505(b)(2) oncology supportive care product for the US market.

As per the agreement, RK Pharma will manufacture and supply the finished product, while Zydus Life will be responsible for the NDA submission and commercialisation of the product in the US, it said.

The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals.

The product targets a significant commercial opportunity in the US market, with an estimated total addressable market of 6.2 million units, as per IQVIA data as of September 2025, the company said.

"This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Sharvil Patel, the managing director of Zydus Life, said.

Ravishanker Kovi, the founder and executive chairman of RK Pharma, said Zydus Life has power commercial footprint, robust regulatory expertise and ensures that this important therapeutic option would reach patients efficiently.

Zydus Life shares were trading nearly 1.5% up at र942 apiece around 1 pm on Wednesday. The stock has declined 7% in the past month.

Also Read: Metal stocks surge in trade — Here are key factors behind the upmove